Royal Bank of Canada started coverage on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a research note released on Thursday morning, Marketbeat reports. The firm issued an outperform rating and a $9.00 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. ValuEngine upgraded shares of Aurinia Pharmaceuticals from a sell rating to a hold rating in a report on Friday, February 2nd. Canaccord Genuity set a $11.00 price target on shares of Aurinia Pharmaceuticals and gave the company a buy rating in a report on Tuesday, October 24th. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, October 24th. BidaskClub upgraded shares of Aurinia Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, January 5th. Finally, HC Wainwright reiterated a buy rating and set a $12.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $10.59.

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.10 on Thursday. Aurinia Pharmaceuticals has a fifty-two week low of $3.21 and a fifty-two week high of $10.54. The company has a market cap of $428.26, a P/E ratio of -4.21 and a beta of 2.38.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. The company’s revenue for the quarter was up .0% compared to the same quarter last year. analysts expect that Aurinia Pharmaceuticals will post -1.08 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its holdings in Aurinia Pharmaceuticals by 8.6% in the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,341 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Aurinia Pharmaceuticals by 13,197.5% in the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 26,395 shares during the last quarter. Cutler Capital Management LLC boosted its holdings in Aurinia Pharmaceuticals by 25.0% in the fourth quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 10,000 shares during the last quarter. Investment Centers of America Inc. boosted its holdings in Aurinia Pharmaceuticals by 100.0% in the third quarter. Investment Centers of America Inc. now owns 60,000 shares of the biotechnology company’s stock worth $376,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Swiss National Bank purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter worth approximately $421,000. Institutional investors own 28.08% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://theolympiareport.com/2018/02/11/aurinia-pharmaceuticals-auph-now-covered-by-analysts-at-royal-bank-of-canada.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.